English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In a recent article, Hassett et al. (1) suggested that chemotherapy-related serious adverse effects among younger women with breast cancer may be more common than reported by large clinical trials. To confi rm this fi nding, we estimated the frequency of chemotherapy-related serious adverse effects among all incident breast cancer cases (n = 3317) that occurred between January 1999 and December 2002 in the female population (aged 69 years or younger) of Milan, Italy. For all patients, information about pathological staging, surgical treatment, radiotherapy, and chemotherapy were available. Information about the starting date and the type of drug used for chemotherapy administered within the 12 months following breast cancer diagnosis was derived, such that all prescriptions (prescribed between January 1999 and December 2003) with their Anatomical, Therapeutic, Chemical

Re: Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer